WO1998024910A3 - Mutants of streptococcal toxin c and methods of use - Google Patents

Mutants of streptococcal toxin c and methods of use Download PDF

Info

Publication number
WO1998024910A3
WO1998024910A3 PCT/US1997/022125 US9722125W WO9824910A3 WO 1998024910 A3 WO1998024910 A3 WO 1998024910A3 US 9722125 W US9722125 W US 9722125W WO 9824910 A3 WO9824910 A3 WO 9824910A3
Authority
WO
WIPO (PCT)
Prior art keywords
spe
toxin
methods
vaccine
mutants
Prior art date
Application number
PCT/US1997/022125
Other languages
French (fr)
Other versions
WO1998024910A2 (en
Inventor
Patrick M Schlievert
Douglas Ohlendorf
David T Mitchell
Pamala J Gahr
Original Assignee
Univ Minnesota
Patrick M Schlievert
Douglas Ohlendorf
David T Mitchell
Pamala J Gahr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US09/308,829 priority Critical patent/US6835818B2/en
Priority to KR1019997005030A priority patent/KR100615836B1/en
Priority to AU76256/98A priority patent/AU734597B2/en
Priority to BR9713679-4A priority patent/BR9713679A/en
Priority to CA002273824A priority patent/CA2273824C/en
Priority to DE69735439T priority patent/DE69735439T2/en
Priority to JP52576698A priority patent/JP2002513278A/en
Priority to EP97949733A priority patent/EP0946730B1/en
Application filed by Univ Minnesota, Patrick M Schlievert, Douglas Ohlendorf, David T Mitchell, Pamala J Gahr filed Critical Univ Minnesota
Publication of WO1998024910A2 publication Critical patent/WO1998024910A2/en
Publication of WO1998024910A3 publication Critical patent/WO1998024910A3/en
Priority to US09/336,036 priority patent/US6774218B2/en
Priority to HK00103559A priority patent/HK1024265A1/en
Priority to US10/914,665 priority patent/US20050010034A1/en
Priority to US10/914,417 priority patent/US20050010033A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence

Abstract

This invention is directed to mutant SPE-C toxins or fragments thereof, vaccine and pharmaceutical compositions, and methods of using the vaccine and pharmaceutical compositions. The preferred SPE-C toxin has at least one amino acid change and is substantially non-lethal compared with the wild type SPE-C toxin. The mutant SPE-C toxins can form vaccine compositions useful to protect animals against the biological activities of wild type SPE-C toxin.
PCT/US1997/022125 1996-12-06 1997-12-05 Mutants of streptococcal toxin c and methods of use WO1998024910A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP52576698A JP2002513278A (en) 1996-12-06 1997-12-05 Mutant streptococcal toxin C and methods of use
AU76256/98A AU734597B2 (en) 1996-12-06 1997-12-05 Mutants of streptococcal toxin C and methods of use
BR9713679-4A BR9713679A (en) 1996-12-06 1997-12-05 Streptococcal toxin c mutants and methods of use
CA002273824A CA2273824C (en) 1996-12-06 1997-12-05 Mutants of streptococcal toxin c and methods of use
DE69735439T DE69735439T2 (en) 1996-12-06 1997-12-05 MUTANTS OF STREPTOCOCCALTOXIN C AND METHOD FOR THEIR APPLICATION
US09/308,829 US6835818B2 (en) 1996-12-06 1997-12-05 Mutants of Streptococcal toxin C and methods of use
EP97949733A EP0946730B1 (en) 1996-12-06 1997-12-05 Mutants of streptococcal toxin c and methods of use
KR1019997005030A KR100615836B1 (en) 1996-12-06 1997-12-05 Mutants of streptococcal toxin C
US09/336,036 US6774218B2 (en) 1996-12-06 1999-06-18 Mutants of streptococcal toxin C and methods of use
HK00103559A HK1024265A1 (en) 1996-12-06 2000-06-14 Mutants of streptococcal toxin c and methods of use
US10/914,665 US20050010034A1 (en) 1997-12-05 2004-08-09 Mutants of streptococcal toxin C and methods of use
US10/914,417 US20050010033A1 (en) 1996-12-06 2004-08-09 Mutants of streptococcal toxin C and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3325196P 1996-12-06 1996-12-06
US60/033,251 1996-12-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/336,036 Continuation-In-Part US6774218B2 (en) 1996-12-06 1999-06-18 Mutants of streptococcal toxin C and methods of use

Publications (2)

Publication Number Publication Date
WO1998024910A2 WO1998024910A2 (en) 1998-06-11
WO1998024910A3 true WO1998024910A3 (en) 1998-09-03

Family

ID=21869358

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/022125 WO1998024910A2 (en) 1996-12-06 1997-12-05 Mutants of streptococcal toxin c and methods of use

Country Status (15)

Country Link
US (1) US6835818B2 (en)
EP (1) EP0946730B1 (en)
JP (1) JP2002513278A (en)
KR (1) KR100615836B1 (en)
CN (1) CN1148449C (en)
AT (1) ATE319830T1 (en)
AU (1) AU734597B2 (en)
BR (1) BR9713679A (en)
CA (1) CA2273824C (en)
DE (1) DE69735439T2 (en)
DK (1) DK0946730T3 (en)
ES (1) ES2260804T3 (en)
HK (1) HK1024265A1 (en)
PT (1) PT946730E (en)
WO (1) WO1998024910A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US7087235B2 (en) * 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
US6872394B1 (en) 1997-12-02 2005-03-29 Idaho Research Foundation, Inc. Non-toxic immune stimulating enterotoxin compositions
US7491402B2 (en) 1998-12-24 2009-02-17 Auckland Uniservices Limited Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof
CA2436856A1 (en) * 2000-12-04 2002-06-13 Auckland Uniservices Limited Immunomodulatory constructs and their uses
SE0102327D0 (en) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
GB0227026D0 (en) * 2002-11-20 2002-12-24 Molecular Skincare Ltd Psoriasis diagnostics and therapeutics
US7299231B2 (en) * 2004-07-29 2007-11-20 International Business Machines Corporation Method and system of subsetting a cluster of servers
CN109195988B (en) 2016-01-10 2023-12-01 尼奥克斯医疗有限公司 Methods and compositions for enhancing the efficacy of superantigen-mediated cancer immunotherapy
US20210292398A1 (en) * 2018-05-16 2021-09-23 Griffith University Streptococcal toxic shock syndrome
MX2021013908A (en) 2019-05-15 2022-03-11 Neotx Therapeutics Ltd Cancer treatment.
AU2021357520A1 (en) 2020-03-05 2022-09-29 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4784948A (en) 1983-08-10 1988-11-15 The Rockefeller University Production of streptococcal m protein immunogens and molecular probes
US5298396A (en) * 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
US5336598A (en) * 1989-11-15 1994-08-09 National Jewish Center For Immunology And Respiratory Medicine Method for diagnosing a superantigen caused pathologial condition via assay of T-cells
WO1993014634A1 (en) 1992-01-28 1993-08-05 National Jewish Center For Immunology And Respiratory Medicine Protective effects of mutated superantigens
US5460813A (en) * 1993-04-05 1995-10-24 National Jewish Center For Immunology And Respiratory Medicine Method for treating Kawasaki syndrome by administration of an anti-TSST-1 agent which is not gamma globulin
AU723116B2 (en) 1995-06-07 2000-08-17 Regents Of The University Of Minnesota Mutants of streptococcal toxin A and methods of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GOSHORN SC ET AL: "Nucleotide sequence of streptococcal pyrogenic exotoxin type C.", INFECT IMMUN, SEP 1988, 56 (9) P2518-20, UNITED STATES, XP002066997 *
HOVDE CJ ET AL: "INVESTIGATION OF THE ROLE OF THE DISULFIDE BOND IN THE ACTIVITY AND STRUCTURE OF STAPHYLOCOCCAL-ENTEROTOXIN C1", MOLECULAR MICROBIOLOGY, 1994, 13, 897-909, XP002067000 *
KLINE, J. BRADFORD ET AL: "Analysis of the superantigenic activity of mutant and allelic forms of streptococcal pyrogenic exotoxin A", INFECT. IMMUN. (1996), 64(3), 861-9 CODEN: INFIBR;ISSN: 0019-9567, XP002066999 *
NORRBYTEGLUND A ET AL: "DETECTION AND NUCLEOTIDE-SEQUENCE ANALYSIS OF THE SPEC GENE IN SWEDISH CLINICAL GROUP A STREPTOCOCCAL ISOLATES", JOURNAL OF CLINICAL MICROBIOLOGY, 1994, 32, 705-709, XP002066998 *

Also Published As

Publication number Publication date
CN1240001A (en) 1999-12-29
CA2273824A1 (en) 1998-06-11
US20020039585A1 (en) 2002-04-04
DE69735439T2 (en) 2006-09-07
HK1024265A1 (en) 2000-10-05
KR100615836B1 (en) 2006-08-25
US6835818B2 (en) 2004-12-28
AU7625698A (en) 1998-06-29
KR20000069337A (en) 2000-11-25
JP2002513278A (en) 2002-05-08
WO1998024910A2 (en) 1998-06-11
CA2273824C (en) 2007-05-08
PT946730E (en) 2006-06-30
CN1148449C (en) 2004-05-05
ATE319830T1 (en) 2006-03-15
EP0946730A2 (en) 1999-10-06
DK0946730T3 (en) 2006-07-10
ES2260804T3 (en) 2006-11-01
EP0946730B1 (en) 2006-03-08
BR9713679A (en) 2001-07-17
AU734597B2 (en) 2001-06-21
DE69735439D1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
EP1538208A3 (en) Mutants of streptococcal toxin A and methods of use
EP1398379A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis
WO1999003884A3 (en) Modified immunogenic pneumolysin, compositions and their use as vaccines
WO1998024910A3 (en) Mutants of streptococcal toxin c and methods of use
WO1998016646A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1998024911A3 (en) Mutants of streptococcal toxin a and methods of use
CA2381770A1 (en) Human ctla-4 antibodies and their uses
WO1999051748A3 (en) Fusion proteins of mycobacterium tuberculosis antigens and their uses
EP1285664A3 (en) Methods of increasing lean tissue mass using OB protein compositions
WO2003051914A3 (en) Ides, an igg-degrading enzyme of streptococcus pyogenes
WO1999042076A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
AU5229498A (en) Mutants of the lag-3 proteins, products for the expression of these mutants and use
BR9712556A (en) Plasmid, pharmaceutical composition, and, process of immunizing an individual against an antigen
WO2000009553A3 (en) Antimicrobial peptides isolated from the skin of american frogs
WO1999001473A3 (en) Anti-bacterial methods and materials
EA200100700A1 (en) GENES AND PROTEINS AND THEIR APPLICATION
AU1239997A (en) Polypeptides corresponding to the amino acid sequences of proteins p57 or p9.5 of Borna disease virus, nucleic acid fragments coding therefore and their use for diagnostic and immunization purposes
ES2171563T3 (en) NEW FAMILY OF PROTEASE INHIBITORS, AND OTHER SUBSTANCES OF BIOLOGICAL ACTIVITY.
CA2169051A1 (en) Rye-Flour
WO2003044047A3 (en) Virulence proteins of the genus yersinia and uses thereof
DE68914397T2 (en) Human lymphotoxin.
AU1720497A (en) Use of primers for universal fingerprint analysis
AU5569600A (en) Novel protein and dna thereof
FR2707492B1 (en) New cosmetic or dermatological compositions containing the ribosomes, preparation of the ribosomes, preparation of the said compositions and their application.
GB9710636D0 (en) Novel mixture

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97180372.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page

Free format text: ADD INID NUMBER (63) "RELATED BY CONTINUATION (CON) OR CONTINUATION-IN-PART (CIP) TO EARLIER APPLICATION" WHICH WAS INADVERTENTLY OMITTED FROM THE FRONT PAGE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2273824

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1019997005030

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1997949733

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 76256/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 09308829

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1997949733

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019997005030

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 76256/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1997949733

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1019997005030

Country of ref document: KR